First Quadrant’s Myriad Genetics MYGN Stock Holding History

First Quadrant’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6,776	Closed	-$77K	–	684
2020 Q2	$77K	Sell	6,776 -13,580	-67%	-$193K	0.01%	605
2020 Q1	$291K	Buy	+20,356	New	+$430K	0.04%	354
2019 Q1	–	Sell	-4,441	Closed	-$129K	–	772
2018 Q4	$129K	Buy	4,441 +80	+2%	+$2.88K	0.01%	609
2018 Q3	$201K	Buy	+4,361	New	+$194K	﹤0.01%	624
2016 Q4	–	Sell	-36,564	Closed	-$752K	–	880
2016 Q3	$752K	Buy	+36,564	New	+$927K	0.02%	481
2014 Q3	–	Sell	-272,700	Closed	-$10.6M	–	832
2014 Q2	$10.6M	Sell	272,700 -197,100	-42%	-$7.33M	0.24%	128
2014 Q1	$16.1M	Sell	469,800 -143,700	-23%	-$4.45M	0.36%	81
2013 Q4	$12.9M	Buy	613,500 +332,800	+119%	+$8.42M	0.3%	102
2013 Q3	$6.6M	Buy	280,700 +193,900	+223%	+$5.51M	0.17%	166
2013 Q2	$2.33M	Buy	+86,800	New	+$2.52M	0.06%	271

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Quadrant's MYGN Position: Q3 2020 in Review

First Quadrant sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 6,776 shares — an estimated $77K sold.

First Quadrant first reported a position in MYGN in Q2 2013 and held it in 10 quarters. The position peaked at $16.1M in Q1 2014. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

First Quadrant reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
First Quadrant sold 6,776 Myriad Genetics shares in Q3 2020, an estimated $77K.
First Quadrant first reported a position in Myriad Genetics in Q2 2013 and held it in 10 quarters.
First Quadrant's Myriad Genetics position peaked at $16.1M in Q1 2014.
192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on First Quadrant's 13F filing for Q3 2020, filed 28 Oct 2020.